Compare MSD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSD | ASMB |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.8M | 553.6M |
| IPO Year | N/A | 2010 |
| Metric | MSD | ASMB |
|---|---|---|
| Price | $7.35 | $36.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 70.2K | ★ 124.4K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,191,000.00 |
| Revenue This Year | N/A | $42.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $6.11 | $7.75 |
| 52 Week High | $7.46 | $39.71 |
| Indicator | MSD | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 57.82 |
| Support Level | $7.35 | $35.05 |
| Resistance Level | $7.41 | $38.82 |
| Average True Range (ATR) | 0.05 | 1.91 |
| MACD | 0.00 | -0.32 |
| Stochastic Oscillator | 60.71 | 42.70 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.